The IMPACT trial shows Pulmonx Corp.'s Zephyr endobronchial valves produces clinically meaningful benefits in improved lung function, exercise tolerance and quality-of-life for patients with homogenous emphysema without collateral ventilation who were selected for the therapy with Pulmonx' Chartis diagnostic tool.
Pulmonx Reaches Multiple Milestones In Lung-Valve, Diagnostics Development
Encouraging results from the IMPACT study of Pulmonx's Zephyr endobronchial valve in patients with homogenous emphysema – a population with almost no other options – is the latest in string of good news for the Silicon Valley company, which wants to create a new paradigm of personalized device therapy for pulmonary disease.
More from R&D
• By
Enovis has named veteran medtech leader Damien McDonald as its new CEO effective 12 May as the orthopedic company reaffirms first-quarter 2025 revenue guidance of between $555m and $563m. Medtech Insight spoke with Tim Czartoski, Enovis’ president of US surgical and global product and enabling technologies, about the firm’s growth strategy and innovation plans.
• By
Abbott presented late-breaking data at the 2025 American College of Cardiology conference demonstrating that TriClip transcatheter edge-to-edge repair offers prolonged patient benefits compared to medical treatment alone after two years, which were not evident at one year.
• By
The Cologuard Plus test has a sensitivity of 95% and a specificity of 94% for the detection of colorectal cancer; “unmatched accuracy,” according to Exact Sciences.
• By
Vektor Medical is ramping up efforts to bring its vMap technology used to identify arrhythmia sources to more US hospitals, start enrollment in a multinational trial, and commercialize in Europe, pending the CE mark. Medtech Insight sat down with CEO Rob Krummen at LSI 2025 to discuss their plans.
More from Business
• By
Leann Sims joins AbundaBox as COO; Oura Ring firm appoints CMO.
• By
Vektor Medical is ramping up efforts to bring its vMap technology used to identify arrhythmia sources to more US hospitals, start enrollment in a multinational trial, and commercialize in Europe, pending the CE mark. Medtech Insight sat down with CEO Rob Krummen at LSI 2025 to discuss their plans.
• By
Only 16% of venture capital general partners in Europe are women, and only 9% of those have actual investment power. Thena Capital is aiming to "redefine the image of a venture capitalist."